Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss treatments like finasteride, dutasteride, and minoxidil are discussed, with differing views on when to begin treatment. Some suggest early use, while others warn of hormonal side effects from starting too young.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

A 21-year-old underwent a hair transplant with 1100 grafts and uses oral minoxidil and topical dutasteride to maintain hair. They experienced side effects with oral finasteride but not with their current regimen.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

A 17-year-old is using oral dutasteride, finasteride, and topical minoxidil for hair loss, with plans to increase dutasteride and consider surgery. They report significant regrowth but are worried about side effects and the effects of blocking DHT at a young age.

The user has been using finasteride and topical minoxidil for hair loss since April 2024 but feels their condition has worsened. They are considering switching to oral minoxidil or dutasteride for better results.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

Dutasteride caused persistent hair shedding and no improvement for 18 months, leading to a switch back to finasteride. The user also uses oral minoxidil and plans to focus on better scalp health.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.

A 73-year-old is considering using Minoxidil or Dutasteride for hair loss. Suggestions include using RU58841, topical treatments, or unconventional methods like wigs and humorous, unrealistic remedies.

The user has been using Finasteride 1mg daily since July 2024 and Estradiol since December 2024, noticing thicker and less oily hair with regrowth at the temples. Other users agree that the hair has improved significantly.

A user shared their 16-year hair loss journey using finasteride and minoxidil, noting slow hair thinning despite a family history of severe balding. They switched from topical to oral minoxidil but stopped for personal reasons, experiencing no significant side effects from finasteride.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A 24-year-old is experiencing aggressive hair loss despite using minoxidil and finasteride for years and is considering a hair transplant. Many suggest trying dutasteride, but there are concerns about side effects.

The conversation discusses hair loss treatments, recommending finasteride, minoxidil, and ketoconazole, with some users suggesting dermarolling and dutasteride. The consensus is that starting treatment early, especially at a young age, can improve chances of hair regrowth.

The user has been using dutasteride and oral minoxidil for 60 days, noticing thin baby hairs on their temples. They are anxious about progress and plan to update after 90 days, while others advise patience.

A user shared their hair loss journey from age 15 to 23, achieving results with finasteride 1mg, oral minoxidil 5mg, and a hair transplant. The conversation includes discussions on the effectiveness of these treatments and questions about the hair transplant process.

A 19-year-old switched from finasteride to dutasteride after two months due to aggressive androgen alopecia and is also using minoxidil and tretinoin. Users advise patience, caution with dutasteride at a young age, and suggest consulting a doctor.

A 16-year-old shared progress pictures after 68 days of using 5% topical minoxidil for hair growth. The conversation focused on confusion about the order of before-and-after photos, with some users commenting on the effectiveness and others on the user's young age and genetics.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

A 23-year-old feels devastated by hair loss despite using Minoxidil and finasteride since age 18, and is advised to embrace baldness, improve physical fitness, and consider hair systems. The conversation emphasizes self-acceptance, confidence, and exploring new interests to improve mental well-being.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.